Targets › MSLN
19 programs from 11 companies in 33 trials: 32 Phase 1, 1 Phase 2; Oncology, Other; next expected readout Dec 2026.
Membrane-anchored forms may play a role in cellular adhesion.; FUNCTION: Megakaryocyte-potentiating factor (MPF) potentiates megakaryocyte colony formation in vitro. (UniProt, Q13421)
Open in Phaseline: the race on MSLN, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Anetumab Ravtansine Mesothelin binding agent; Tubulin inhibitor | MSLN, Tubulin | Phase 2 | Fallopian Tube Endometrioid Adenocarcinoma; Pancreatic Adenocarcinoma; Pleural Malignant Mesothelioma | Jan 2027 |
| Chinese PLA General Hospital | Pan-T booster co-expressing MSLN CAR T cell anti-MSLN CAR-T cell therapy with CD40 agonist and T cell costimulator agonist | MSLN | Phase 1 | Advanced or Metastatic Solid Tumors | Dec 2026 |
| Shenzhen University General Hospital | MSLN CAR-T Anti-MSLN chimeric antigen receptor T-cell therapy | MSLN | Phase 1 | Advanced Solid Malignant Tumors (With Positive Expression of MSLN in Tumor Tissue) | Jan 2027 |
| Beijing Biotech | EB-DNK101 dual-targeting CAR-NK cells (MSLN + MUC1) Allogeneic CAR-NK cells with dual-recognition CAR targeting MSLN and MUC1 | MSLN, MUC1 | Phase 1 | Pancreatic Ductal Adenocarcinoma (PDAC) | Feb 2027 |
| Beijing Biotech | EB-G3B7-NK dual-target CAR-NK cells Dual-targeting CAR-NK cells directed against IL13Rα2, EGFR/EGFRvIII, or B7-H3 (CD276) expr | CD276, MSLN, EGFR, ERBB2, IL13RA2 | Phase 1 | Non-Small Cell Lung Cancer; Breast Cancer (Locally Advanced or Metastatic); Glioblastoma; Advanced Hepatocellular Carcinoma (HCC) … | Feb 2027 |
| Beijing Biotech | EB-NK-MF CAR-NK cells Dual-targeting CAR-NK cells engineered to target Mesothelin and Folate Receptor alpha (wit | MSLN, FOLR1, MUC16, TROP2 | Phase 1 | Advanced Solid Tumors; Epithelial Ovarian Cancer | Feb 2027 |
| Beijing Biotech | EB-MF-CAR-NK-01 Dual-target CAR-NK cells recognizing mesothelin-positive tumor cells and FAP-positive stro | MSLN, FAP | Phase 1 | Malignant Pleural Mesotheliomas | Mar 2027 |
| Beijing Biotech | EB-CARMSLN-NK Mesothelin-targeted allogeneic CAR-NK cells | MSLN | Phase 1 | B2 Thymoma | Jun 2027 |
| Memorial Sloan Kettering Cancer Center | Mesothelin-targeted T cells CAR-T cells targeting mesothelin | MSLN | Phase 1 | Breast Cancer | Jun 2027 |
| Memorial Sloan Kettering Cancer Center | M28z1XXPD1DNR CAR T cells Mesothelin-targeted CAR T cells with anti-PD1 component | MSLN, PDCD1 | Phase 1 | Malignant Pleural Mesothelioma (MPM); Mesothelin Positive | Sep 2027 |
| Essen Biotech | Mesothelin and Claudin 18.2 CAR-T cells Dual-target CAR-T cells targeting Mesothelin and Claudin 18.2 | MSLN, CLDN18 | Phase 1 | Pancreatic Cancer | Dec 2027 |
| Tianjin Medical University Cancer Institute and Hospital | CHT102 mesothelin-targeting UCAR-T cells | MSLN | Phase 1 | Advanced Pancreatic Cancers | Dec 2027 |
| A2 Biotherapeutics | A2B543 Mesothelin-targeting logic-gated CAR T cell therapy | MSLN | Phase 1 | Solid Tumor, Adult | Jun 2028 |
| A2 Biotherapeutics | A2B694 Mesothelin-targeting logic-gated CAR T cell therapy | MSLN | Phase 1 | Solid Tumor, Adult | Jun 2028 |
| Second Affiliated Hospital of Guangzhou Medical University | Mesothelin/GPC3/GUCY2C-CAR-T cells CAR-T cells targeting mesothelin, GPC3, and GUCY2C; second generation with IL-21/anti-PD-1 | MSLN, GPC3, GUCY2C | Phase 1 | Pancreas Cancer | Mar 2029 |
| Second Affiliated Hospital of Guangzhou Medical University | GPC3/Mesothelin-CAR-γδT cells GPC3/Mesothelin-targeted CAR-γδT cell therapy | GPRC3, MSLN | Phase 1 | Pancreas Cancer | Nov 2030 |
| National Cancer Institute (NCI) | TNhYP218 CAR T Cells anti-mesothelin CAR-T cell therapy | MSLN | Phase 1 | Mesothelioma | Jun 2034 |
| Context Therapeutics | CT-95 MSLN bispecific antibody | MSLN | Phase 1 | Mesothelin-Expressing Tumors | – |
| Zhongda Hospital | TCR-like CAR-T TCR-like CAR-T cell therapy targeting MSLN | MSLN | Phase 1 | Safety and Efficacy of TCR-like CAR-T | – |
Pancreatic Ductal Adenocarcinoma (PDAC) (4) Pancreas Cancer (2) Epithelial Ovarian Cancer (2) Non-Small Cell Lung Cancer (2) Solid Tumor, Adult (2) Mesothelioma (1) Malignant Pleural Mesothelioma (MPM) (1) Mesothelin Positive (1) Advanced Solid Tumors (1) Fallopian Tube Endometrioid Adenocarcinoma (1) Pancreatic Adenocarcinoma (1) Pleural Malignant Mesothelioma (1)
mixed (10), other (5), small molecule (2), protein or peptide (2)
Beijing Biotech (5) Second Affiliated Hospital of Guangzhou Medical University (2) National Cancer Institute (NCI) (2) Memorial Sloan Kettering Cancer Center (2) A2 Biotherapeutics (2) Chinese PLA General Hospital (1) Tianjin Medical University Cancer Institute and Hospital (1) Zhongda Hospital (1) Shenzhen University General Hospital (1) Essen Biotech (1) Context Therapeutics (1)
GPRC3 (1) PDCD1 (1) FOLR1 (1) MUC16 (1) TROP2 (1) MUC1 (1) Tubulin (1) FAP (1) CD276 (1) EGFR (1) ERBB2 (1) IL13RA2 (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.